• Celgene’s luspatercept aces phase 3 beta thalassemia trial fiercebiotech
    January 03, 2019
    A phase 3 trial of Celgene’s luspatercept in adults with beta thalassemia has hit its primary goal. The late-phase success tees Celgene to file for approval of its Acceleron-partnered blockbuster prospect in the first half of next year......
PharmaSources Customer Service